Germany approves Phase 1/2 trial of KYV-101 for lupus nephritis

Kyverna Therapeutics is planning to launch a Phase 1/2 trial in Germany to test KYV-101, its investigational cell therapy for lupus nephritis, a lupus complication characterized by kidney damage. The study was approved by the Paul Ehrlich Institute (PEI), which is responsible for examining clinical trials of investigational…

Benlysta Helps Lupus Patients Improve, German Study Indicates

Most lupus patients who added Benlysta (belimumab) to their treatment regimen improved, according to research in Germany. Seventy-eight percent of the systemic lupus erythematosus (SLE) patients in the study showed improved health after six months of Benlysta treatment, doctors said. In addition, 42 percent of patients reported feeling better.